GB201004200D0 - Spirocyclic compounds and their use as therapeutic agents and diagnostic probes - Google Patents

Spirocyclic compounds and their use as therapeutic agents and diagnostic probes

Info

Publication number
GB201004200D0
GB201004200D0 GBGB1004200.0A GB201004200A GB201004200D0 GB 201004200 D0 GB201004200 D0 GB 201004200D0 GB 201004200 A GB201004200 A GB 201004200A GB 201004200 D0 GB201004200 D0 GB 201004200D0
Authority
GB
United Kingdom
Prior art keywords
therapeutic agents
diagnostic probes
spirocyclic compounds
spirocyclic
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1004200.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Basel
Original Assignee
Universitaet Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Basel filed Critical Universitaet Basel
Priority to GBGB1004200.0A priority Critical patent/GB201004200D0/en
Publication of GB201004200D0 publication Critical patent/GB201004200D0/en
Priority to US13/635,016 priority patent/US20130040934A1/en
Priority to EP11715742A priority patent/EP2547684A1/en
Priority to SG2012068094A priority patent/SG184062A1/en
Priority to CN2011800239958A priority patent/CN102939292A/zh
Priority to MX2012010655A priority patent/MX2012010655A/es
Priority to PCT/IB2011/051047 priority patent/WO2011114275A1/en
Priority to JP2012557645A priority patent/JP2013522286A/ja
Priority to BR112012023320A priority patent/BR112012023320A2/pt
Priority to RU2012143689/04A priority patent/RU2012143689A/ru
Priority to KR1020127026689A priority patent/KR20130086520A/ko
Priority to CA2791737A priority patent/CA2791737A1/en
Priority to NZ602292A priority patent/NZ602292A/en
Priority to AU2011228703A priority patent/AU2011228703A1/en
Priority to ZA2012/06580A priority patent/ZA201206580B/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
GBGB1004200.0A 2010-03-15 2010-03-15 Spirocyclic compounds and their use as therapeutic agents and diagnostic probes Ceased GB201004200D0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
GBGB1004200.0A GB201004200D0 (en) 2010-03-15 2010-03-15 Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
AU2011228703A AU2011228703A1 (en) 2010-03-15 2011-03-11 Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
PCT/IB2011/051047 WO2011114275A1 (en) 2010-03-15 2011-03-11 Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
BR112012023320A BR112012023320A2 (pt) 2010-03-15 2011-03-11 compostos espirocíclicos e sua utilização como agentes terapêuticos e sondas de diagnóstico
SG2012068094A SG184062A1 (en) 2010-03-15 2011-03-11 Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
CN2011800239958A CN102939292A (zh) 2010-03-15 2011-03-11 螺环化合物及其作为治疗剂和诊断探针的用途
MX2012010655A MX2012010655A (es) 2010-03-15 2011-03-11 Compuestos espirociclicos y su uso como agentes terapeuticos y sondas de diagnostico.
US13/635,016 US20130040934A1 (en) 2010-03-15 2011-03-11 Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
JP2012557645A JP2013522286A (ja) 2010-03-15 2011-03-11 スピロ環化合物ならびに治療薬及び診断プローブとしてのその使用
EP11715742A EP2547684A1 (en) 2010-03-15 2011-03-11 Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
RU2012143689/04A RU2012143689A (ru) 2010-03-15 2011-03-11 Спироциклические соединения и их применение в качестве терапевтических агентов и диагностических зондов
KR1020127026689A KR20130086520A (ko) 2010-03-15 2011-03-11 스피로시클릭 화합물 및 이들의 치료제 및 진단 프로브로서 용도
CA2791737A CA2791737A1 (en) 2010-03-15 2011-03-11 Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
NZ602292A NZ602292A (en) 2010-03-15 2011-03-11 Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
ZA2012/06580A ZA201206580B (en) 2010-03-15 2012-09-03 Spirocyclic compounds and thier use as therapeutic agents and diagnostic probes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1004200.0A GB201004200D0 (en) 2010-03-15 2010-03-15 Spirocyclic compounds and their use as therapeutic agents and diagnostic probes

Publications (1)

Publication Number Publication Date
GB201004200D0 true GB201004200D0 (en) 2010-04-28

Family

ID=42261530

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1004200.0A Ceased GB201004200D0 (en) 2010-03-15 2010-03-15 Spirocyclic compounds and their use as therapeutic agents and diagnostic probes

Country Status (15)

Country Link
US (1) US20130040934A1 (https=)
EP (1) EP2547684A1 (https=)
JP (1) JP2013522286A (https=)
KR (1) KR20130086520A (https=)
CN (1) CN102939292A (https=)
AU (1) AU2011228703A1 (https=)
BR (1) BR112012023320A2 (https=)
CA (1) CA2791737A1 (https=)
GB (1) GB201004200D0 (https=)
MX (1) MX2012010655A (https=)
NZ (1) NZ602292A (https=)
RU (1) RU2012143689A (https=)
SG (1) SG184062A1 (https=)
WO (1) WO2011114275A1 (https=)
ZA (1) ZA201206580B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140069235A (ko) 2011-09-27 2014-06-09 노파르티스 아게 돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
EP2970240B1 (en) 2013-03-14 2018-01-10 Novartis AG 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
UY35464A (es) 2013-03-15 2014-10-31 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
PH12019502378A1 (en) 2013-05-01 2022-05-11 Hoffmann La Roche Biheteroaryl compounds and uses thereof
CN103483345B (zh) * 2013-09-25 2016-07-06 中山大学 Pi3k激酶抑制剂、包含其的药物组合物及其应用
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
CN104557871B (zh) * 2013-10-28 2017-05-03 上海汇伦生命科技有限公司 具有螺环取代基的芳基吗啉类化合物，其制备方法和用途
LT3134432T (lt) 2014-04-25 2020-04-10 Bluebird Bio, Inc. Mnd promotorius chimerinių antigenų receptoriams
NZ725201A (en) 2014-04-25 2018-05-25 Bluebird Bio Inc Improved methods for manufacturing adoptive cell therapies
SI3151672T1 (sl) 2014-06-06 2021-03-31 Bluebird Bio, Inc. Izboljšani T-celični sestavki
MX2017001079A (es) 2014-07-24 2017-09-12 Bluebird Bio Inc Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
DK3212637T3 (da) 2014-10-31 2021-07-12 Indivior Uk Ltd Dopamin-d3-receptorantagonistforbindelser
EA036379B1 (ru) 2014-12-12 2020-11-02 Блубёрд Био, Инк. Химерные антигенные рецепторы к bcma
US11479755B2 (en) 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions
EP3231799A1 (en) * 2016-04-14 2017-10-18 Universität Basel 4-(azetidin-1-yl)pyrimidine derivatives with anti-mitotic and anti-proliferative activity
KR20240005168A (ko) 2016-11-04 2024-01-11 2세븐티 바이오, 인코포레이티드 항-bcma car t 세포 조성물
CA3044771A1 (en) * 2016-12-21 2018-06-28 Japan Tobacco Inc. Crystalline forms of a janus kinase inhibitor
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
AU2018271990A1 (en) 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
JP7340519B2 (ja) * 2017-11-06 2023-09-07 メッドシャイン ディスカバリー インコーポレイテッド ｍＴＯＲＣ１／２二重阻害剤としてのピリドピリミジン系化合物
CN108191837A (zh) * 2018-01-10 2018-06-22 贵州医科大学 PI3Kα/mTOR双激酶抑制剂及其药物组合物和应用
MX2021000887A (es) * 2018-08-01 2021-03-31 Araxes Pharma Llc Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
WO2021113506A1 (en) * 2019-12-04 2021-06-10 Chdi Foundation, Inc. Atm kinase inhibitors and compositions and methods of use thereof
JP7554829B2 (ja) * 2019-12-19 2024-09-20 ヤンセン ファーマシューティカ エヌ．ベー． 置換直鎖スピロ誘導体
JP7654071B2 (ja) * 2020-10-20 2025-03-31 アムジエン・インコーポレーテツド 複素環スピロ化合物及び使用方法
US20250206729A1 (en) * 2023-12-22 2025-06-26 Deciphera Pharmaceuticals, Llc Dual raf and tubulin inhibitors and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1389617B1 (en) 2001-04-27 2007-01-03 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
AU2006217742A1 (en) 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited Hydrazinomethyl, HYDR zonomethyl and 5-membered heterocylic compounds which act as MTOR inhibitors and their use as anti cancer agents
GB0525081D0 (en) * 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2008032072A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032033A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008098058A1 (en) * 2007-02-06 2008-08-14 Novartis Ag Pi 3-kinase inhibitors and methods of their use
GB0721095D0 (en) * 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
WO2009140128A2 (en) * 2008-05-13 2009-11-19 Irm Llc Compounds and compositions as kinase inhibitors
AP2775A (en) * 2008-05-23 2013-09-30 Wyeth Llc Triazine compounds as P13 kinase and MTOR inhibitors

Also Published As

Publication number Publication date
EP2547684A1 (en) 2013-01-23
CN102939292A (zh) 2013-02-20
US20130040934A1 (en) 2013-02-14
AU2011228703A1 (en) 2012-09-20
MX2012010655A (es) 2012-10-05
RU2012143689A (ru) 2014-04-20
NZ602292A (en) 2014-08-29
CA2791737A1 (en) 2011-09-22
KR20130086520A (ko) 2013-08-02
WO2011114275A1 (en) 2011-09-22
SG184062A1 (en) 2012-10-30
BR112012023320A2 (pt) 2016-05-24
ZA201206580B (en) 2013-05-29
JP2013522286A (ja) 2013-06-13

Similar Documents

Publication Publication Date Title
GB201004200D0 (en) Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
LT2364302T (lt) Triazino analogai ir jų panaudojimas kaip terapinių agentų ir diagnostikos zonų
GB2499174B (en) Self-contained patient monitor
DK2608777T3 (en) Compositions and Methods for Cardiac Therapy
IL232229A0 (en) Diagnostics accompanying treatment with an anti-hyaluronan factor and methods of using it
GB201004020D0 (en) New therapeutic use
ZA201205432B (en) Compositions and methods for the diagnosis and treatment of tumor
PL3260128T3 (pl) Zastosowanie medyczne rozpuszczalnego CD24
GB0918392D0 (en) Diagnostic and therapeutic methods
EP2646821A4 (en) NEOANTIC BODY FOR THE DIAGNOSIS OF TISSUE INJURY
IL232824A0 (en) Medical and/or diagnostic nanocarriers targeting mmp
GB201004924D0 (en) Medical/cosmetic device
GB201011411D0 (en) Therapeutic compounds and their use
EP2833877A4 (en) NEW TARGETING AGENTS FOR DIAGNOSTIC AND THERAPEUTIC INDICATIONS
EP2635189A4 (en) PORTABLE DEVICE FOR EX-VIVO STIMULATION OF WHOLE BLOOD
EP2420189A4 (en) ULTRASOUND DIAGNOSTIC DEVICE
EP2623147A4 (en) MEDICAL INSTRUMENT WITH A NEEDLE INSTALLED THEREIN
ZA201308101B (en) Diagnostic use of prosomatostatin
GB201204014D0 (en) Diagnostic marker compounds and their use
GB201016461D0 (en) Medical instrument
SI2566579T1 (sl) Medicinska naprava za magnetoterapijo
PL2364302T3 (pl) Analogi triazyny i ich zastosowanie jako środki terapeutyczne oraz sondy diagnostyczne
PT2364302T (pt) Análogos de triazina e a sua utilização como agentes terapêuticos e sondas de diagnóstico
AU2010900773A0 (en) Therapeutic and diagnostic agents
GB201009483D0 (en) Therapeutic use of imidazopyridine compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)